Evidence map›Paper›PMID 40894196›Full record

ArticleFrontiers in pharmacology2025

FGFC1 overcomes Ara-C resistance in acute myeloid leukemia by inducing apoptosis and pyroptosis.

Xiaohui Hu, Zhijian Li, Rui Zhou, Bing Zhang, Ruoxian Wang, Tongtong Li, Jiangcheng Chang, Wenhui Wu, Ning Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. An Alkaloid from MarinePharmaceuticals (Basel, Switzerland) · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xiaohui Hu *International Research Centre for Food and Health, College of Food Science and Technology, Shanghai Ocean University, Shanghai, China.
Zhijian Li *International Research Centre for Food and Health, College of Food Science and Technology, Shanghai Ocean University, Shanghai, China.
Rui ZhouInternational Research Centre for Food and Health, College of Food Science and Technology, Shanghai Ocean University, Shanghai, China.
Bing ZhangInternational Research Centre for Food and Health, College of Food Science and Technology, Shanghai Ocean University, Shanghai, China.
Ruoxian WangInternational Research Centre for Food and Health, College of Food Science and Technology, Shanghai Ocean University, Shanghai, China.
Tongtong LiInternational Research Centre for Food and Health, College of Food Science and Technology, Shanghai Ocean University, Shanghai, China.
Jiangcheng ChangInternational Research Centre for Food and Health, College of Food Science and Technology, Shanghai Ocean University, Shanghai, China.
Wenhui WuInternational Research Centre for Food and Health, College of Food Science and Technology, Shanghai Ocean University, Shanghai, China.
Ning LiuInternational Research Centre for Food and Health, College of Food Science and Technology, Shanghai Ocean University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute myeloid leukemia (AML) is a hematologic malignancy with a high mortality rate and poor prognosis, largely attributed to the emergence of chemotherapy resistance. Cytarabine (Ara-C), the cornerstone chemotherapeutic agent for AML, faces significant challenges due to the development of resistance, creating an urgent need for novel therapeutic strategies. Pyroptosis as a new form of programmed cell death has emerged as a potential therapeutic target in tumor treatment. However, its role in overcoming Ara-C resistance in AML by modulating pyroptosis remains unexplored. FGFC1 (Fungi fibrinolytic compound 1) a natural compound derived from

Indexed as

acute myeloid leukemia (AML)apoptosis and pyroptosiscytarabine (Ara-C) resistanceFGFC1GSDME

Identifiers

PMID40894196
PMCPMC12391149

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.